kiromic exists to create a robust diagnostic and therapeutic program for solid tumors and hematologic malignancies based on its portfolio of patented cancer-associated biomarkers and small molecules. kiromic aims to develop clinical diagnostic tools for rapid detection of cancer-associated antigens, which may translate into earlier diagnosis and accurate monitoring of response to cancer treatments. our cancer-associated biomarkers also allow for the design and development of personalized, cancer-specific targeted immunotherapy strategies that may improve patient outcomes and result in less suffering and longer survival times.
Company profile
Ticker
KRBP
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Kiromic, Inc.
SEC CIK
Corporate docs
Subsidiaries
GreenPlanet Pharma, Inc • InSilico Solutions, LLC ...
IRS number
464762913
KRBP stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
19 Apr 24
RW
Registration withdrawal request
10 Apr 24
8-K
Entry into a Material Definitive Agreement
5 Apr 24
8-K
Entry into a Material Definitive Agreement
2 Apr 24
10-K/A
2023 FY
Annual report (amended)
21 Mar 24
10-K
2023 FY
Annual report
18 Mar 24
8-K
Entry into a Material Definitive Agreement
11 Mar 24
8-K
Entry into a Material Definitive Agreement
14 Feb 24
8-K
Entry into a Material Definitive Agreement
11 Jan 24
8-K
Entry into a Material Definitive Agreement
15 Dec 23
Latest ownership filings
4
Michael Catlin
20 Mar 24
4
Pamela Misajon
20 Mar 24
4
MICHAEL NAGEL
20 Mar 24
SC 13G/A
YA II PN, Ltd.
12 Feb 24
SC 13D
BERSANI PIETRO
8 Feb 24
SC 13G/A
Empery Asset Management, LP
8 Jan 24
SC 13G/A
SABBY MANAGEMENT, LLC
2 Jan 24
4
PIETRO BERSANI
6 Oct 23
4
Pamela Misajon
6 Oct 23
4
MICHAEL NAGEL
6 Oct 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.38 mm | 4.38 mm | 4.38 mm | 4.38 mm | 4.38 mm | 4.38 mm |
Cash burn (monthly) | (no burn) | (no burn) | 1.85 mm | 1.80 mm | 1.74 mm | 1.66 mm |
Cash used (since last report) | n/a | n/a | 12.76 mm | 12.38 mm | 12.02 mm | 11.45 mm |
Cash remaining | n/a | n/a | -8.38 mm | -8.00 mm | -7.64 mm | -7.07 mm |
Runway (months of cash) | n/a | n/a | -4.5 | -4.5 | -4.4 | -4.3 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 6 |
Opened positions | 0 |
Closed positions | 3 |
Increased positions | 0 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 6.66 mm |
Total shares | 2.18 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
YA II PN | 1.69 mm | $542.00 k |
Empery Asset Management | 491.55 k | $0.00 |
Tower Research Capital | 1.40 k | $3.81 mm |
BLK Blackrock | 809.00 | $2.20 mm |
MS Morgan Stanley | 40.00 | $109.00 k |
Group One Trading | 1.00 | $3.00 k |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Mar 24 | Michael Catlin | Restricted Stock Award | Grant | Acquire A | No | No | 0 | 18,000 | 0.00 | 25,500 |
18 Mar 24 | Pamela Misajon | Restricted Stock Award | Grant | Acquire A | No | No | 0 | 18,000 | 0.00 | 25,500 |
18 Mar 24 | Michael Nagel | Restricted Stock Award | Grant | Acquire A | No | No | 0 | 18,000 | 0.00 | 42,296 |
5 Oct 23 | Michael Catlin | RSU Common Stock | Grant | Acquire A | No | No | 0 | 7,500 | 0.00 | 7,500 |
5 Oct 23 | Brian Hungerford | RSU Common Stock | Grant | Acquire A | No | No | 0 | 21,900 | 0.00 | 21,900 |
Press releases
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
24 Apr 24
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
2 Apr 24
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial
19 Mar 24
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
1 Mar 24
Kiromic BioPharma to Present at the OTC Markets' Virtual Life Science Investor Forum on March 7th
28 Feb 24